Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

News

Scrip World Pharmaceutical News was established in 1972 and - since that time - has continued to serve as the leading news and information source for the world's pharmaceutical and biotech industries. Scrip's team of more than 20 writers, analysts and editors provide the latest news, features and commentary from around the globe.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report.

    For further information please contact:
    ThromboGenics
    Dr. Patrik De Haes, CEO
    Tel: +32-16-75-13-10
    patrik.dehaes@thrombogenics.com

    Chris Buyse, CFO
    Tel: +32-16-75-13-10
    chris.buyse@thrombogenics.com

    Citigate Dewe Rogerson
    Amber Bielecka/ David Dible/ Nina Enegren
    Tel: +44-207-638-95-71
    amber.bielecka@citigatedr.co.uk



'/>"/>
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... 12, 2014 This report ... used in the life science industry. Continuous ... science reagents market towards remarkable growth. The ... providers of life science reagents. , Brows ... http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global life science ...
(Date:7/11/2014)... DUBLIN , July 11, 2014 ... "International Transfection Technology Market - Global Industry Analysis, ... report to their offering. ... to introduce nucleic acids (either DNA or RNA) into ... therapy, mutation of cancer cells and protein metabolism by ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... Faso (PRWEB) July 10, 2014 ... today have access to an additional family planning ... access to contraception at all levels of the ... lower-dose formulation of a widely used contraceptive—Pfizer’s Depo-Provera® ... , Burkina Faso is the first of four ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6
... TurboSonic,Technologies, Inc. (OTC Bulletin Board: TSTA), a global ... control technologies, today,announced that the company,s CEO, Edward Spink ... Show., The interview gives viewers an overview of ... release., To view the clip ...
... sinus irrigation device) describes his successful treatment protocol for ... cavities using a pulsating irrigation device. This treatment has ... of sinus infections, snoring and sleep apnea., http://abclocal.go.com/kabc/story?section=news/health&id=6231390 ... ...
... Department of Labor Conference, WEST PALM BEACH, ... Department of Labor,s Recognition of Excellence Award in,the ... Deputy Assistant Secretary of Labor for Employment and,Training, ... honors,workforce investment programs from around the country that ...
Cached Biology Technology:[video] Edward Spink, CEO of TurboSonic Technologies, Inc. Discusses Contract With Biofuel Producer in Exclusive Interview on WallSt.net's 3-Minute Press Show 2Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation 2Workforce Alliance Receives U.S. Labor Department's Excellence Award 2Workforce Alliance Receives U.S. Labor Department's Excellence Award 3
(Date:7/11/2014)... July 11, 2014 Research and Markets ... Biometrics Technology Market - Industry Analysis Size Share Growth ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... has created a need for high level security in ... personnel authentication such as username and passwords, tokens etc. ...
(Date:7/11/2014)... Brazil- In the brains of all vertebrates, information ... an electric or chemical signal to be passed ... which are the most abundant type of synapse, ... is crucial for learning, memory, perception and cognition, ... critical for brain function. For instance, every ...
(Date:7/10/2014)... Colo. , June 27, 2014  The ... the National Institute of Standards and Technology (NIST) ... of its academic research and forensic science expert ... The Board is an element of the NIST,s ... members are among the first appointments made to ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Blame it on the astrocytes 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... Juvenile Diabetes Research Foundation, a leader in setting the ... will begin a diabetes research collaboration with Pfizer, Hadassah ... drugs to replicate and regenerate insulin-producing cells in people ... the direction of Professor Benjamin Glaser (Hadassah Medical) and ...
... Medical Center have identified a new growth factor that ... cells in culture and in laboratory animals. The discovery, ... help researchers overcome one of the most frustrating barriers ... are so few in number and so stubbornly resistant ...
... Spanish . , Feeding the amino acid tryptophan ... makes them less aggressive and easier to manage, according to ... The tryptophan-enhanced diet reduced aggression and overall behavioral activity ... is only acquired through diet, is the precursor for the ...
Cached Biology News:JDRF, Pfizer, Hadassah Medical and the Hebrew University announce collaboration 2Newly identified growth factor promotes stem cell growth, regeneration 2Tryptophan-enriched diet reduces pig aggression 2
Anti Autotaxin /ENPP2 , - (Rabbit)...
...
... 2-Deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose Pale yellow solid. An ... a nitric oxide donor in pancreatic ... bacteria. Causes DNA alkylation and DNA ... Purity: ≥95% by HPLC. Soluble in ...
... a silica based spin filter membrane to isolate ... DNA band is cut from an agarose gel ... The gel slice is melted irreversibly in a ... bound to the silica spin filter membrane and ...
Biology Products: